Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2015

Date: November 18, 2015
Pages: 30
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U9A3C571762EN
Leaflet:

Download PDF Leaflet

Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2015’, provides an overview of the Upsher-Smith Laboratories, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Upsher-Smith Laboratories, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Upsher-Smith Laboratories, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Upsher-Smith Laboratories, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Upsher-Smith Laboratories, Inc.’s pipeline products
Reasons to buy
  • Evaluate Upsher-Smith Laboratories, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Upsher-Smith Laboratories, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Upsher-Smith Laboratories, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Upsher-Smith Laboratories, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Upsher-Smith Laboratories, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Upsher-Smith Laboratories, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Upsher-Smith Laboratories, Inc. Snapshot
Upsher-Smith Laboratories, Inc. Overview
Key Information
Key Facts
Upsher-Smith Laboratories, Inc. - Research and Development Overview
Key Therapeutic Areas
Upsher-Smith Laboratories, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Upsher-Smith Laboratories, Inc. - Pipeline Products Glance
Upsher-Smith Laboratories, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Upsher-Smith Laboratories, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Upsher-Smith Laboratories, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Upsher-Smith Laboratories, Inc. - Drug Profiles
midazolam hydrochloride
Product Description
Mechanism of Action
R&D Progress
naluzotan hydrochloride
Product Description
Mechanism of Action
R&D Progress
PRX-167700
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Protein Kinase for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize CXCR4 for Inflammation and Glioblastoma Multiforme
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize PAR-2 for Atopic Dermatitis, Inflammatory Bowel Disease and Ulcerative Colitis
Product Description
Mechanism of Action
R&D Progress
Upsher-Smith Laboratories, Inc. - Pipeline Analysis
Upsher-Smith Laboratories, Inc. - Pipeline Products by Target
Upsher-Smith Laboratories, Inc. - Pipeline Products by Route of Administration
Upsher-Smith Laboratories, Inc. - Pipeline Products by Molecule Type
Upsher-Smith Laboratories, Inc. - Pipeline Products by Mechanism of Action
Upsher-Smith Laboratories, Inc. - Recent Pipeline Updates
Upsher-Smith Laboratories, Inc. - Dormant Projects
Upsher-Smith Laboratories, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Upsher-Smith Laboratories, Inc., Key Information
Upsher-Smith Laboratories, Inc., Key Facts
Upsher-Smith Laboratories, Inc. - Pipeline by Indication, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Stage of Development, 2015
Upsher-Smith Laboratories, Inc. - Monotherapy Products in Pipeline, 2015
Upsher-Smith Laboratories, Inc. - Phase III, 2015
Upsher-Smith Laboratories, Inc. - Phase II, 2015
Upsher-Smith Laboratories, Inc. - Preclinical, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Target, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Route of Administration, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Molecule Type, 2015
Upsher-Smith Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2015
Upsher-Smith Laboratories, Inc. - Recent Pipeline Updates, 2015
Upsher-Smith Laboratories, Inc. - Dormant Developmental Projects,2015
Upsher-Smith Laboratories, Inc., Other Locations
Upsher-Smith Laboratories, Inc., Subsidiaries

LIST OF FIGURES

Upsher-Smith Laboratories, Inc. - Pipeline by Top 10 Indication, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Stage of Development, 2015
Upsher-Smith Laboratories, Inc. - Monotherapy Products in Pipeline, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Top 10 Target, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Top 10 Route of Administration, 2015
Upsher-Smith Laboratories, Inc. - Pipeline by Top 10 Molecule Type, 2015
Upsher-Smith Laboratories, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: